United Therapeutics (UTHR) Gross Margin (2009 - 2026)

United Therapeutics has disclosed Gross Margin across 18 years of filings, most recently posting 87.3% for Q2 2026.

• In Q2 2026, Gross Margin fell 173.0% year-over-year to 87.3%; the TTM figure through Jun 2026 stood at 86.14% (down 284.0% YoY), while the FY2025 annual figure was 87.92%, down 131.0% from the prior year.
• Gross Margin came in at 87.3% for Q2 2026 at United Therapeutics, up from 82.93% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 94.39% in Q1 2022 to a low of 82.93% in Q1 2026.
• Average Gross Margin over 5 years is 89.09%, with a median of 88.97% recorded in 2024.
• Year-over-year, Gross Margin jumped 197 bps in 2022 and slumped 543 bps in 2026.
• Over 5 years, Gross Margin stood at 88.04% in 2022, then advanced by 0 bps to 88.45% in 2023, then increased by 1 bps to 89.69% in 2024, then retreated by 3 bps to 86.91% in 2025, then grew by 0 bps to 87.3% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 87.3% in Q2 2026, 82.93% in Q1 2026, and 86.91% in Q4 2025.